Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma

Background: Recent advances in the development of tyrosine kinase inhibitors (TKIs) have enabled patients with unresectable hepatocellular carcinoma (HCC) to receive multiple TKIs in sequence. The aim of this study was to identify predictors of good candidates for second-line treatment after disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Hitomi, Kurosaki, Masayuki, Tsuchiya, Kaoru, Komiyama, Yasuyuki, Itakura, Jun, Takahashi, Yuka, Nakanishi, Hiroyuki, Yasui, Yutaka, Tamaki, Nobuharu, Maeyashiki, Chiaki, Kaneko, Shun, Takaura, Kenta, Higuchi, Mayu, Okada, Mao, Wang, Wan, Osawa, Leona, Sekiguchi, Shuhei, Hayakawa, Yuka, Yamashita, Koji, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770447/
https://www.ncbi.nlm.nih.gov/pubmed/31461985
http://dx.doi.org/10.3390/cancers11091256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770447/
https://www.ncbi.nlm.nih.gov/pubmed/31461985
http://dx.doi.org/10.3390/cancers11091256

Ejemplares similares